Mylan N.V., a global pharmaceutical company committed to setting new standards in healthcare, announced the US launch of Efavirenz tablets USP, 600 mg, the first generic version of Bristol-Myers Squibb's Sustiva. The product is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 infection in adults and in paediatric patients at least 3 months old and weighing at least 3.5 kg.

Mylan is the world's largest producer of HIV/AIDS drugs, and more than 40% of the world's 20 million people being treated worldwide for HIV/AIDS depend on a Mylan antiretroviral product. In the US, there are an estimated 1.1 million people living with HIV.

"With the launch of Efavirenz, Mylan marks an important achievement in bringing more affordable treatment options to the HIV patient community," said Mylan CEO Heather Bresch. "Our global commitment to improving access to antiretroviral medicines for this important patient population spans more than a decade, and the US launch bolsters our leadership in producing high-quality ARVs and positions us to continue to lead this important category in the future."

According to the FDA approval letter, Mylan was one of the first applicants to submit a substantially complete ANDA for Efavirenz tablets USP, 600 mg, containing a Paragraph IV certification, and is eligible for 180 days of generic drug exclusivity. Efavirenz tablets USP, 600 mg, had US sales of approximately $113 million for the 12 months ending December 31, 2017, according to IQVIA.

Currently, Mylan has 208 ANDAs pending FDA approval representing approximately $93.2 billion in annual brand sales, according to IQVIA. Forty-six of these pending ANDAs are potential first-to-file opportunities, representing $42.1 billion in annual brand sales, for the 12 months ending July 31, 2017, according to IQVIA.

For more than a decade, Mylan has been a leader in providing access to quality, dependable and affordable ARVs in more than 100 countries around the world. This includes introducing in 2009 the first generic one-tablet-once-a-day combination for developing countries - only three years after the originator product launched in the US. Since that time, Mylan has been the first to market with nearly half of the new products approved under the FDA's U.S. President's Emergency Plan for AIDS Relief (PEPFAR) program. Mylan was also the first generic drug maker to develop a heat-stable version of a drug critical for second-line regimens, and is the leading supplier of pediatric ARVs, including taste-masked and dispersible formulations. Mylan has also long been a supporter of the patient community through the sponsorship of free community HIV/AIDS testing and clinical research. Learn more about Mylan's work with infectious disease here. Watch this video to learn more about Mylan's commitment to people living with HIV/AIDS.